Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.17T
Market cap1.17T
Price-Earnings ratio
43.51
Price-Earnings ratio43.51
Dividend yield
0.50%
Dividend yield0.50%
Average volume
2.56M
Average volume2.56M
High today
$1,242.00
High today$1,242.00
Low today
$1,235.50
Low today$1,235.50
Open price
$1,274.78
Open price$1,274.78
Volume
17.72K
Volume17.72K
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$694.23
52 Week low$694.23

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,240.62, giving the company a market capitalization of 1.17T. It carries a P/E multiple of 43.51 and pays a dividend yield of 0.50%.

On 2026-08-21, Eli Lilly(LLY) stock traded between a low of $1,235.50 and a high of $1,242.00. Shares are currently priced at $1,240.62, which is +0.4% above the low and -0.1% below the high.

The Eli Lilly(LLY)'s current trading volume is 17.72K, compared to an average daily volume of 2.56M.

During the past year, Eli Lilly(LLY) stock moved between $694.23 at its lowest and $1,292.65 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $694.23 at its lowest and $1,292.65 at its peak.

LLY News

Investor's Business Daily 56m
Eli Lilly Is In A Race with Novo Nordisk But Its Stock Is The Clear Winner

These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Tops Buy Point 8/21/2026 Among the best stocks in earnings performance, highly...

Eli Lilly Is In A Race with Novo Nordisk But Its Stock Is The Clear Winner
TipRanks 2h
Eli Lilly Buy Rating Reiterated on Durable Incretin and Obesity Growth, Price Target Maintained at $1,344

Analyst Jason Gerberry from Bank of America Securities maintained a Buy rating on Eli Lilly & Co and keeping the price target at $1,344.00. Unlock powerful inv...

Investor's Business Daily 18h
Deere Soars: Energy Infrastructure, Data Centers Fuel (At Last) An Earnings Gain

Stocks To Watch: 14 Names Test And Tease New Buy Zones 7/08/2026 A barrage of stocks to watch like Eli Lilly and Deere, show promise, alongside reminders to ke...

Deere Soars: Energy Infrastructure, Data Centers Fuel (At Last) An Earnings Gain

Analyst ratings

82%

of 33 ratings
Buy
81.8%
Hold
12.1%
Sell
6.1%

More LLY News

TipRanks 20h
Lilly’s Mirikizumab Breast Milk Study Adds A New Layer To Immunology Safety Data

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more co...

TipRanks 20h
Eli Lilly Advances Early-Stage Eloralintide Trial: What Investors Should Watch

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more co...

TipRanks 21h
Eli Lilly’s Lebrikizumab Trial Completion Signals New Growth Path in Atopic Dermatitis

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more co...

Simply Wall St 1d
How Eli Lilly’s Global Vault CRM Rollout At Veeva Systems Has Changed Its Investment Story

Earlier this month, Eli Lilly and Company committed to deploy Veeva Vault CRM globally as part of Veeva’s Vault CRM Suite supporting agentic commercial workflow...

How Eli Lilly’s Global Vault CRM Rollout At Veeva Systems Has Changed Its Investment Story
Simply Wall St 1d
Will Foundayo’s UK GLP‑1 Approval and New R&D Deals Change Eli Lilly's Narrative?

In recent days, Eli Lilly announced multiple R&D agreements, including global rights to AlzeCure’s preclinical Alzheimer’s candidate ACD680 with potential miles...

Will Foundayo’s UK GLP‑1 Approval and New R&D Deals Change Eli Lilly's Narrative?
Nasdaq 2d
Could Eli Lilly Be Worth More Than SpaceX by the End of 2026?

Key Points Eli Lilly is highly profitable and has been growing fast due to its popular GLP-1 drugs. SpaceX's stock went public recently and has been incredibl...

Could Eli Lilly Be Worth More Than SpaceX by the End of 2026?
Investor's Business Daily 2d
Dow Jones Futures: S&P 500, Nasdaq Rise On Treasury Move; Moderna, Merck Spur Big Biopharma Gains

Stock Market Today Dow Jones Futures: S&P 500, Nasdaq Rise On Treasury Move; Moderna, Merck Spur Big Biopharma Gains Licensing Dow Jones futures were little cha...

Dow Jones Futures: S&P 500, Nasdaq Rise On Treasury Move; Moderna, Merck Spur Big Biopharma Gains

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.